The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Jun 2021 09:08

RNS Number : 3076B
Avacta Group PLC
09 June 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BYYW9G87

Issuer Name

AVACTA GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Conifer Management, L.L.C.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

04-Jun-2021

6. Date on which Issuer notified

08-Jun-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

2.990000

0.000000

2.990000

7575786

Position of previous notification (if applicable)

3.540000

0.000000

3.540000

8333333

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYYW9G87

7575786

0

2.990000

0.000000

Sub Total 8.A

7575786

2.990000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Gregory Alexander

Conifer Management, LLC

2.990000

0.000000

2.990000

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Shares are held in private funds managed by Conifer Management, LLC.

12. Date of Completion

08-Jun-2021

13. Place Of Completion

New York, USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLGZGGVRLKGMZG
Date   Source Headline
2nd Oct 20187:00 amRNSPreliminary Results
21st Sep 20187:00 amRNSInvestor Meeting and Presentation
5th Sep 20187:15 amEQSHardman & Co Research: Avacta (AVCT): Capital increase for further development
5th Sep 20187:00 amRNSNotice of Results
31st Aug 20189:55 amRNSHolding(s) in Company
23rd Aug 20185:07 pmRNSHolding(s) in Company
23rd Aug 20185:06 pmRNSHolding(s) in Company
23rd Aug 201811:21 amRNSHolding(s) in Company
22nd Aug 20182:23 pmRNSHolding(s) in Company
22nd Aug 20189:20 amRNSHolding(s) in Company
17th Aug 201811:30 amRNSResult of General Meeting
6th Aug 20184:24 pmRNSHolding(s) in Company
30th Jul 20186:06 pmRNSResults of Placing and Subscription
30th Jul 201811:41 amRNSProposed Placing and Subscription to raise £11.4m
30th Jul 201810:35 amEQSHardman & Co Research: Avacta (AVCT): Ground-breaking new drug conjugate platform
24th Jul 20187:00 amRNSMajor Therapeutics Co-development Partnership
26th Jun 20181:30 pmEQSHardman & Co Research: Avacta (AVCT): Gearing up the management team
11th Jun 20187:00 amRNSAppointment of Non-Executive Chairman
31st May 201812:15 pmEQSHardman & Co Research: Avacta (AVCT): In vivo expression of Affimers
22nd May 20187:00 amRNSSuccessful Outcome of Study with FIT Biotech
30th Apr 20184:45 pmRNSHolding(s) in Company
17th Apr 20187:17 amEQSHardman & Co Research: Avacta (AVCT): Commendable rate of progress
16th Apr 20187:25 amRNSInterim Results
9th Apr 20182:58 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAvacta to Present at Investor Forum
29th Mar 20187:00 amRNSDirectorate Change
13th Mar 201812:02 pmRNSDirector/PDMR Shareholding
7th Mar 20184:35 pmRNSPrice Monitoring Extension
8th Feb 20187:00 amRNSSummary of Capital Markets Day
22nd Jan 20187:00 amRNSAvacta and OncoSec to Collaborate
18th Jan 201811:26 amRNSResult of Annual General Meeting
18th Jan 20187:00 amRNSAGM Business Update and Notice of Results
15th Jan 201810:58 amRNSHardmanResearch: Affimer Drug Conjugates a reality
15th Jan 20187:00 amRNSDrug Development Partnership with Glythera
8th Jan 20187:00 amRNSCapital Markets Day Notification
4th Jan 201811:04 amRNSPDMR Dealing and Issue of Equity
3rd Jan 20187:00 amRNSPresenting at the Biotech Showcase, San Francisco
18th Dec 20174:28 pmRNSIssue of Equity
4th Dec 201711:03 amRNSPosting of Annual Report and Notice of AGM
30th Nov 201710:57 amRNSIssue of Equity
15th Nov 20177:00 amRNSCovance to Present Affimer Data at Conference
14th Nov 20173:27 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSAvacta to present at PEGS Europe
13th Nov 20177:00 amRNSAvacta to Present at Investor Evening
24th Oct 20177:00 amRNSAffimers in Scientific Publications
19th Oct 20177:00 amRNSPrivate Shareholder Update Event
16th Oct 201710:42 amRNSHardman Res.: R&D accelerated to advance assets
12th Oct 20177:00 amRNSAvacta to Present at Shares Spotlight Evening
10th Oct 20177:00 amRNSAvacta to Present at Major US Conference
9th Oct 20174:02 pmRNSDirector Dealing and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.